1H-吡唑-3-羧酸,4-硝基-,甲基酯 | 123743-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1H-吡唑-3-羧酸,4-硝基-,甲基酯
• 中文别名: 4-(甲基-亚硝基氨基)-4-吡啶-3-基丁酸
• 英文名称: 4-(Methylnitrosamino)-4-(3-pyridyl)butyric acid
• 英文别名: 4-[methyl(nitroso)amino]-4-pyridin-3-ylbutanoic acid
• CAS: 123743-84-0
• 化学式: C₁₀H₁₃N₃O₃
• 分子量: 223.23
• InChiKey: NZSNJPDBPMIBSP-UHFFFAOYSA-N

物化性质

• 溶解度：
  DMSO（少许）、甲醇（少许）、水（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  82.9
• 氢给体数：
  1
• 氢受体数：
  6

ADMET

代谢

Iso-NNAC 是尼古丁的一种已知的第三手烟雾代谢物。

Iso-NNAC is a known thirdhand smoke metabolite of Nicotine.

来源:NORMAN Suspect List Exchange

文献信息

• [EN] MOLECULARLY IMPRINTED POLYMERS SELECTIVE FOR NITROSAMINES AND METHODS OF USING THE SAME<br/>[FR] POLYMERES A EMPREINTES MOLECULAIRES SELECTIFS DES NITROSAMINES ET PROCEDES D'UTILISATION DESDITS POLYMERES
  申请人：MIP TECHNOLOGIES AB

  公开号：WO2005112670A1

  公开（公告）日：2005-12-01

  A class of molecularly imprinted polymers that specifically recognizes and binds to nitrosamines members of which class are useful, for example, in analysis and separation of nitrosamines from biological fluids. Such molecularly imprinted polymers are also useful in methods of treating and manufacturing tobacco products and materials.

  一类分子印迹聚合物，专门识别和结合亚硝胺成员，例如在分析和从生物体液中分离亚硝胺方面非常有用。这种分子印迹聚合物还可用于治疗和制造烟草产品和材料的方法。
• Fibrous filtration material for electronic smoking article
  申请人：RAI Strategic Holdings, Inc.

  公开号：US10383369B2

  公开（公告）日：2019-08-20

  The present disclosure relates to aerosol delivery devices, methods of forming such devices, and elements of such devices. Some aerosol delivery devices of the current disclosure include a reservoir having a liquid aerosol precursor composition, an electrical heater in fluid communication with the reservoir and configured to vaporize the liquid aerosol precursor composition to form an aerosol, and a filter operatively arranged relative to the electrical heater such that at least a portion of the formed aerosol passes therethrough, the filter being configured to selectively bind one or more undesirable impurities.

  本公开涉及气溶胶输送装置、形成此类装置的方法以及此类装置的元件。本公开的一些气溶胶输送装置包括一个具有液态气溶胶前体组合物的贮存器、一个与贮存器流体连通并被配置成使液态气溶胶前体组合物气化以形成气溶胶的电加热器，以及一个相对于电加热器操作性地布置成至少一部分所形成的气溶胶从其中通过的过滤器，该过滤器被配置成选择性地结合一个或多个不需要的杂质。
• Tobacco having reduced tobacco specific nitrosamine content
  申请人：U.S. Smokeless Tobacco Company LLC

  公开号：US10357055B2

  公开（公告）日：2019-07-23

  The present document generally relates to methods and materials involved in producing tobacco or smokeless tobacco product comprising chlorate. For example, chlorate can be used to reduce tobacco specific nitrosamine content in tobacco or smokeless tobacco products.

  本文件一般涉及生产含有氯酸盐的烟草或无烟烟草制品的方法和材料。例如，氯酸盐可用于降低烟草或无烟烟草制品中的烟草特定亚硝胺含量。
• Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
  申请人：Solis Herrera Arturo

  公开号：US10639300B2

  公开（公告）日：2020-05-05

  Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)-(1-methyl-2-pyrrolidinyl)-pyridine, or a pharmaceutically acceptable salt, analog, precursor or derivative thereof. The methods can be used to treat a wide variety of conditions of the nasal or paranasal mucous membrane, such as nasal congestion and nose bleeds.

  本文描述了治疗和预防鼻腔或副鼻腔粘膜疾病的方法。这些方法包括施用药物组合物，其中包括烟碱乙酰胆碱受体（nAChR）激动剂，如(S)-(1-甲基-2-吡咯烷基)-吡啶，或其药学上可接受的盐、类似物、前体或衍生物。这些方法可用于治疗鼻腔或副鼻黏膜的各种疾病，如鼻塞和鼻出血。
• Reduced risk tobacco products and methods of making same
  申请人：Vector Tobacco Inc.

  公开号：US10709164B2

  公开（公告）日：2020-07-14

  Embodiments provided herein concern tobacco and tobacco products having a reduced amount of a harmful compound. More specifically, several embodiments concern approaches to modify the expression of a gene that is involved in the production of a harmful compound in tobacco, tobacco products made using these approaches and methods of determining whether the removal of said compounds using said approaches yields a tobacco and/or a tobacco product that has a reduced potential to contribute to a tobacco-related disease.

  本文提供的实施方案涉及有害化合物含量降低的烟草和烟草制品。更具体地说，几个实施方案涉及改变烟草中参与产生有害化合物的基因表达的方法、使用这些方法制造的烟草制品以及确定使用所述方法去除所述化合物是否会产生烟草和/或烟草制品的方法，这种烟草和/或烟草制品导致烟草相关疾病的可能性降低。